The physician-developed microbiome company expands beyond supplements with a precision gut health test — and a personalized roadmap for what to do next DALLAS, May 22, 2026 /PRNewswire/ -- resbiotic® (res), a leading physician-developed microbiome health company, today announced the launch of the at-home resbiotic Gut Health Test in partnership with Tiny Health, a precision microbiome platform that delivers a comprehensive picture of gut health — and a clear, personalized plan for improving it.

Parker Waichman, a national law firm, has now filed multiple lawsuits where each Plaintiff alleged that he or she developed NAION after taking Novo Nordisk's Ozempic or Wegovy. PORT WASHINGTON, N.Y., May 22, 2026 /PRNewswire/ -- Parker Waichman has now filed multiple lawsuits on behalf of victims who were prescribed Ozempic or Wegovy and developed NAION, an irreversible eye condition that causes partial or complete permanent vision loss in one or both eyes. On May 8, 2026, the Firm filed a laws

Gilead has at long last won US approval of its hepatitis D treatment Hepcludex, which the FDA previously rejected over issues with its manufacturing and distribution. The drug, known generically as bulevirtide, treats chronic hepatitis D infections in patients who aren’t yet in the later stages of liver damage. Until now, there were no US-approved treatments for the condition, the FDA said in an announcement Friday. Hepcludex has been available in Europe for several years. But the FDA rejected t

Issued on behalf of Conexeu Sciences Inc. Companies mentioned: Conexeu Sciences Inc. (NASDAQ: CNXU), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Evolus, Inc. (NASDAQ: EOLS), Bioventus Inc. (NASDAQ: BVS), Mesoblast Limited (NASDAQ: MESO) KEY TAKEAWAYS A fresh Nasdaq debut. Conexeu Sciences Inc. (Nasdaq: CNXU) began trading on May 21, 2026, marking the public-market entry of a Reno-based regenerative tissue platform company targeting wound care, breast reconstruction, and aesthetic m

WILMINGTON, Del.--(BUSINESS WIRE)--May 22, 2026 — AstraZeneca and Daiichi Sankyo’s DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval follows Priority Review by the Food and Drug Administration (FDA) based on results from the TROPION-Breast02 Phase III trial which were presented at the 2025 European Society

DELRAY BEACH, Fla., May 22, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Protein Expression Market is projected to grow from about USD 5.14 billion in 2026 to USD 7.65 billion by 2031, at a CAGR of 8.3%. Browse 250 market data Tables and 50 Figures spread through 300 Pages and in-depth TOC on 'Electrosurgery Market - Global Forecast to 2031' Protein Expression Market Size & Forecast: Market Size Available for Years: 2025–2031 2026 Market Size: USD 5.14 billion 2031 Projected Market

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced five upcoming presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2026 Congress. The ASCO annual meeting will be held

Educational wellness guide explores NAD+ support, DNA repair support, and long-term cellular wellness routinesRegenix Labs: A wellness-focused company committed to ingredient transparency and sustainable healthy aging routines. NEWARK, Del., May 22, 2026 (GLOBE NEWSWIRE) -- Regenix Labs LLC announces the release of its NMN Supplement, a wellness-focused formulation designed to support cellular vitality, healthy aging routines, DNA repair support, and NAD+ level support as part of a long-term

A key Republican congressman asked the Trump administration to restrict the stream of money into China’s biotech sector, threatening to squelch the dealmaking that’s become big business for some US investment companies and large pharma. Rep. John Moolenaar (R-MI) told Treasury Secretary Scott Bessent in a letter Thursday that the department should add biotechnology to one of the sectors prohibited from receiving outbound US investment under the COINS Act. Signed in December 2025, the law restric

Daiichi Sankyo and AstraZeneca’s Datroway is the only TROP2 directed antibody drug conjugate to prolong overall survival in this setting versus chemotherapy, with an unprecedented median overall survival of approximately two years based on the TROPION-Breast02 phase 3 trial Datroway has the potential to become the new standard of care in this setting TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved